Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:0070004 |
| Name | myeloid neoplasm |
| Definition | A bone marrow cancer that is formed of any one of the bone marrow cells belonging to the granulocytic (neutrophil, eosinophil, basophil), monocytic/macrophage, erythroid, megakaryocytic and mast cell lineages. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01885897 | Phase Ib/II | Nogapendekin alfa inbakicept | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
| NCT02420860 | Phase II | Famotidine Elotuzumab + Lenalidomide Diphenhydramine Dexamethasone | Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT) | Active, not recruiting | USA | 0 |
| NCT02506959 | Phase II | Dexamethasone Busulfan + Melphalan Pyridoxine Panobinostat Palifermin Gemcitabine | Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma | Completed | USA | 0 |
| NCT02843074 | Phase II | Dexamethasone + Elotuzumab + Lenalidomide | Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients | Completed | USA | 0 |
| NCT02969837 | Phase II | Carfilzomib + Dexamethasone + Elotuzumab + Lenalidomide | Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT03503968 | Phase Ib/II | MDG1011 | TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | Terminated | DEU | 0 |
| NCT03531918 | Phase Ib/II | Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone Cladribine + Cytarabine + Filgrastim | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm | Completed | USA | 0 |
| NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT04189445 | Phase II | Futibatinib | Futibatinib in Patients With Specific FGFR Aberrations | Terminated | USA | TUR | SWE | NLD | ITA | GBR | FRA | ESP | DEU | BEL | 5 |
| NCT04195945 | Phase II | CPX-351 Cladribine + Cytarabine + Filgrastim + Mitoxantrone | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | Active, not recruiting | USA | 0 |
| NCT04797767 | Phase Ib/II | Cladribine + Cytarabine + Mitoxantrone + Sargramostim + Venetoclax | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | Recruiting | USA | 0 |